According to Archimedes Pharma, the European Commission has granted marketing authorization for the company’s PecFent fentanyl nasal spray for the treatment of breakthrough pain in adult cancer patients. Archimedes submitted an NDA for the product to the US FDA in 2009 and is waiting for US approval. Read the company’s press release.
Marketing authorization for PecFent nasal spray
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
